A5017177249- Glioma Diagnosis and Treatment
- Brain Metastases and Treatment
- Radiomics and Machine Learning in Medical Imaging
- Meningioma and schwannoma management
- Cancer, Hypoxia, and Metabolism
- Cell death mechanisms and regulation
- Immunotherapy and Immune Responses
- Cancer Genomics and Diagnostics
- CAR-T cell therapy research
- Cancer Immunotherapy and Biomarkers
- CNS Lymphoma Diagnosis and Treatment
- Epigenetics and DNA Methylation
- Neuroblastoma Research and Treatments
- Cell Adhesion Molecules Research
- TGF-β signaling in diseases
- Histone Deacetylase Inhibitors Research
- RNA Interference and Gene Delivery
- Cancer Treatment and Pharmacology
- Immune Cell Function and Interaction
- Ferroptosis and cancer prognosis
- Lymphoma Diagnosis and Treatment
- Cancer-related Molecular Pathways
- Cancer Cells and Metastasis
- Cancer Research and Treatments
- Medical Imaging Techniques and Applications
University of Zurich
2016-2025
University Hospital of Zurich
2016-2025
Neurological Surgery
2006-2024
ETH Zurich
2013-2024
Erasmus MC Cancer Institute
2017-2024
The Netherlands Cancer Institute
2024
Mayo Clinic
2021-2024
University Hospital of Geneva
2024
University of Tübingen
2007-2023
Heinrich Heine University Düsseldorf
2007-2023
Glioblastoma, the most common primary brain tumor in adults, is usually rapidly fatal. The current standard of care for newly diagnosed glioblastoma surgical resection to extent feasible, followed by adjuvant radiotherapy. In this trial we compared radiotherapy alone with plus temozolomide, given concomitantly and after radiotherapy, terms efficacy safety.Patients diagnosed, histologically confirmed were randomly assigned receive (fractionated focal irradiation daily fractions 2 Gy 5 days...
Epigenetic silencing of the MGMT (O6-methylguanine–DNA methyltransferase) DNA-repair gene by promoter methylation compromises DNA repair and has been associated with longer survival in patients glioblastoma who receive alkylating agents.
Tumor-treating fields (TTFields) is an antimitotic treatment modality that interferes with glioblastoma cell division and organelle assembly by delivering low-intensity alternating electric to the tumor.To investigate whether TTFields improves progression-free overall survival of patients glioblastoma, a fatal disease commonly recurs at initial tumor site or in central nervous system.In this randomized, open-label trial, 695 whose was resected biopsied had completed concomitant...
Clinical outcomes for glioblastoma remain poor. Treatment with immune checkpoint blockade has shown benefits in many cancer types. To our knowledge, data from a randomized phase 3 clinical trial evaluating programmed death-1 (PD-1) inhibitor therapy have not been reported.To determine whether single-agent PD-1 nivolumab improves survival patients recurrent compared bevacizumab.In this open-label, randomized, trial, 439 at first recurrence following standard radiation and temozolomide were...
Bevacizumab is approved for the treatment of patients with progressive glioblastoma on basis uncontrolled data. Data from a phase 2 trial suggested that addition bevacizumab to lomustine might improve overall survival as compared monotherapies. We sought determine whether combination would result in longer than alone among at first progression glioblastoma.We randomly assigned after chemoradiation 2:1 ratio receive plus (combination group, 288 patients) or (monotherapy 149 patients). The...
Purpose The standard of care for anaplastic gliomas is surgery followed by radiotherapy. NOA-04 phase III trial compared efficacy and safety radiotherapy chemotherapy at progression with the reverse sequence in patients newly diagnosed gliomas. Patients Methods (N = 318) were randomly assigned 2:1:1 (A:B1:B2) to receive conventional (arm A); procarbazine, lomustine (CCNU), vincristine (PCV; arm B1); or temozolomide B2) diagnosis. At occurrence unacceptable toxicity disease progression, A...